Allergan’s Aesthetic Device Lineup Gains Momentum In 2nd Quarter
This article was originally published in The Gray Sheet
Executive Summary
Allergan's core device sales soared 53.6% in the second quarter from a year ago to $197 million, building momentum for the firm's medical aesthetic products in "rapidly expanding markets," the firm reported Aug. 1
You may also be interested in...
Silicone Breast Implant Approvals Conditioned On Huge Postmarket Studies
FDA's Nov. 17 approval of silicone-gel breast implants comes with the requirement for one of the largest post-approval studies ever called for by the device center, according to CDRH Director Dan Schultz
Wrinkle-Filling Market-Leader Medicis Ready To Take On Juvederm
Medicis says the superior formulation of its Restylane dermal filler will enable it to fend off looming competition from a lower-priced offering by pharmaceutical powerhouse Allergan
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”